Fig. 7
The impacts of DNMT3a and TET2 expression on sorafenib sensitivity. (a and b), SorafenibR Hep3b and Huh7 cells were infected with DNMT3a or TET2 shRNA or control viruses, and selected by 2 µg/ml puromycin for 2 days. Then these cells were exposed to 2 µM sorafenib followed by IncuCyte proliferation assays. (c) and (d), SorafenibR Hep3b and Huh7 cells were infected with DNMT3a or TET2 shRNA or control viruses, and selected by 2 µg/ml puromycin for 2 days. Then these cells were exposed to 2 µM sorafenib followed by wound-healing assays. (e and f), SorafenibR Hep3b and Huh7 cells were infected with either DNMT3a and TET2 shRNA viruses alone or both, selected by 2 µg/ml puromycin for 2 days and subjected to IncuCyte proliferation assays. Data represents two independent experiments with 12 repeats in total. *P < 0.05; Scr, Scramble; Sora, Sorafenib